Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22760907 | 0.96 | STS (0.35) | STSSMN1; SMN2HIF1APRF1CHEK1 | |
| SCHEMBL22761170 | 0.94 | SMN1; SMN2 (0.37) | SMN1; SMN2HIF1APRF1CHEK1ADRA2C | |
| SCHEMBL22760934 | 0.94 | STS (0.35) | STSSMN1; SMN2HIF1APRF1CHEK1 | |
| SCHEMBL22760886 | 0.92 | CHEK1 (0.35) | PRF1CHEK1ADRA2CADORA2AADORA1 | |
| SCHEMBL21546509 | 0.92 | ADRA2C (0.36) | PRF1CHEK1ADRA2CADORA2AADORA1 | |
| SCHEMBL21546966 | 0.91 | CHEK1 (0.36) | SMN1; SMN2HIF1APRF1CHEK1ADRA2C | |
| SCHEMBL22760819 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2HIF1APRF1CHEK1ADRA2C | |
| SCHEMBL22760915 | 0.90 | CHEK1 (0.35) | SMN1; SMN2HIF1APRF1CHEK1ADRA2C | |
| SCHEMBL22760903 | 0.90 | STS (0.35) | STSSMN1; SMN2HIF1APRF1CHEK1 | |
| SCHEMBL22760699 | 0.88 | CHEK1 (0.38) | PRF1CHEK1ADRA2CADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981930-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200385399-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981930-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OR51E2, EPCAM | STS 2957/4885SMN1; SMN2 4427/4885HIF1A 4031/4885 |
| US-20200385399-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, OR51E2, EPCAM | STS 2957/4885SMN1; SMN2 4427/4885HIF1A 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.